CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ibritumomab tiuxetan (Zevalin) Non-Hodgkin’s Lymphoma (NHL) – Details

Brand Name Zevalin
Generic Name Ibritumomab tiuxetan
Tumour Type Lymphoma
Indication Non-Hodgkin’s Lymphoma (NHL)
Review Status Not Filed
Manufacturer Servier Canada Inc.
Submission Type Non-Submission
Clarification CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.
Last Updated June 17, 2019